Zebrafish Screen for Ototoxic and Otoprotective Agents

Information

  • Research Project
  • 7285590
  • ApplicationId
    7285590
  • Core Project Number
    R44DC007767
  • Full Project Number
    5R44DC007767-03
  • Serial Number
    7767
  • FOA Number
    PA-06-06
  • Sub Project Id
  • Project Start Date
    8/1/2005 - 19 years ago
  • Project End Date
    2/28/2009 - 15 years ago
  • Program Officer Name
    CHEN, WEN G.
  • Budget Start Date
    9/1/2007 - 17 years ago
  • Budget End Date
    8/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/23/2007 - 17 years ago

Zebrafish Screen for Ototoxic and Otoprotective Agents

[unreadable] DESCRIPTION (provided by applicant): This SBIR aims to develop a quantitative in vivo zebrafish hair cell assay that can be used to identify potential otoprotective agents. Zebrafish is a useful animal model for identifying otoprotectants since neuromast hair cells, which are located in stereotypical positions in the head and trunk region, are structurally and functionally similar to the inner ear hair cells in mammals. Human hair cells can be damaged by infection, aging, genetic disease, noise or treatment with drugs, including anti-cancer drugs and antibiotics. Drug-induced ototoxicity can ultimately lead to sensory hair cell death, causing hearing loss and vestibular disorders. Although hearing aids are useful for some patients with hearing loss, there is no effective therapy. Current therapeutic strategies include application of growth factors and other agents to promote cell survival, and systemic application of drugs to prevent activation of programmed cell death. The proposed zebrafish assay will facilitate development of protective treatments to minimize ototoxic side effects and increase the clinical utility of current medications. Hearing loss from ototoxic therapies, aging, environmental and genetic factors, represents a significant market with unmet medical needs. In the United States, the market for hearing loss is currently at $30 billion and is expected to increase rapidly in the next several decades. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
  • Activity
    R44
  • Administering IC
    DC
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    406935
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    173
  • Ed Inst. Type
  • Funding ICs
    NIDCD:406935\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLONIX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES